Continuous Loading of a Conservative Trap from an Atomic Beam

We demonstrate the fast accumulation of Cr atoms in a conservative potential from a magnetically guided atomic beam. Without laser cooling on a cycling transition, a single dissipative step realized by optical pumping allows to load atoms at a rate of 2*10^7 1/s in the trap. Within less than 100 ms we reach the collisionally dense regime, from which we directly produce a Bose-Einstein condensate with subsequent evaporative cooling. This constitutes a new approach to degeneracy where, provided a slow beam of particles can be produced by some means, Bose-Einstein condensation can be reached for species without a cycling transition.Comment: 4 pages, 4 figure

Evaporation limited loading of an atom trap

Recently, we have experimentally demonstrated a continuous loading mechanism for an optical dipole trap from a guided atomic beam [1]. The observed evolution of the number of atoms and temperature in the trap are consequences of the unusual trap geometry. In the present paper, we develop a model based on a set of rate equations to describe the loading dynamics of such a mechanism. We consider the collision statistics in the non-uniform trap potential that leads to twodimensional evaporation. The comparison between the resulting computations and experimental data allows to identify the dominant loss process and suggests ways to enhance the achievable steady-state atom number. Concerning subsequent evaporative cooling, we find that the possibility of controlling axial and radial confinement independently allows faster evaporation ramps compared to single beam optical dipole traps.Comment: 10 pages, 7 figure

Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma

Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options

Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma

Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options